No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
HRTS250117C27000
- 0.00
- 0.000.00%
15min DelayClose Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest27.00Strike Price0.00Turnover0.00%IV-8.91%PremiumJan 17, 2025Expiry Date2.64Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
The GLP-1 Makers to Add to Your Portfolio: Tema ETFs CEO
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
This Weight-loss ETF Has Performed Well in Its First Five Months. How Does It Compare With Cheaper Alternatives?
If you're afraid the “Nolly” stock price will rise, consider this ETF that tracks “diet drug bulls”
Tema Pharmaceuticals and Investments (US stock code: HRTS), an ETF that tracks many pharmaceutical companies focused on the diet drug circuit, can be described as a very good choice. Industry ETF portfolios are diversified, and the volatility is often far less than individual stocks.